With official shortages ended, but the first generics gearing up for launch, companies are looking for the next generation of ...

Novo and Lilly’s campaigns are not limited to advertisements alone, and both companies are trying to raise awareness around obesity through research studies and conferences.

As FDA shortages lift, patients and physicians explore new options for continued treatment with compounded GLP-1 medications.

FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 – glucagon-like peptide-1 receptor agonists – drugs, including semaglutide and tirzepatide, as an ...

While weight-loss drugs like Zepbound (LLY) and Wegovy (NVO) offer significant health benefits, their high costs make them ...

Megan Stalter, who portrays Kayla in the Max drama "Hacks," slammed those who lie about taking Ozempic for weight-loss ...

Two new class action complaints, both captioned Robins v. Lemme Inc., were filed in in California Superior Court and the Southern District of New ...

He and his team then compared the diagnoses for hair loss in these patients’ medical records and found that those prescribed ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...

Does ‘Nature’s Ozempic’ exist? Experts say it's complicated. While some supplements could cause a small amount of weight loss ...

Wegovy is a prescription medication designed for chronic weight management, offering hope to individuals struggling with ...